Siloam Mochtar Riady Comprehensive Cancer Center Semanggi Hospital (MRCCC) has been trusted to be the official healthcare partner in organizing the 2024 Asia Pacific Breast Cancer Summit (APBCS).
The meeting, which took place from 1 to 3 March 2024 at the Nusa Dua Convention Center, Bali, Indonesia, brought together global, regional and local experts and researchers to improve the care of breast cancer patients, in accordance with the theme “Reaching New Heights in Breast Cancer Care”.
On this occasion, as many as 10 (ten) experts from MRCCC also participated both as speakers and as panelists.
Chief Organizer of APBCS 2024 Shaheenah Dawood said, “For more than 12 years, APBCS has developed into the main platform in the field of breast cancer management in the Asia Pacific region. The impact of APBCS has resonated in various regions of the Asia Pacific and Indonesia marking a new chapter in the journey of the 12th APBCS in 2024. APBCS 2024 will be a gathering of experts dedicated to pushing the boundaries of knowledge in the field of breast cancer.”
“Apart from that, we also welcome MRCCC’s contribution to this event as an official healthcare partner and sent expert doctors to the 2024 APBCS event to share insights in the field of breast cancer,” he continued.
Meanwhile, MRCCC Director Adityawati Ganggaiswari said, “The 2024 APBCS event which will take place over 3 (three) days, includes sessions on oncology surgery, oncology nursing, imaging, Best of SABCS reviews, and in-depth discussions on advanced findings, latest developments, molecular tumors, as well as challenging cases in APBCS. For this reason, we feel it is very necessary to participate in this event because there are always the latest findings and treatment methods. “Apart from that, we are very proud to be part of APBCS 2024 as an official healthcare partner.”
Also read: Breast Cancer Awareness Month, Siloam Hospitals Runs the SELANGKAH Program
The energy experts from MRCCC who were also present were:
- Jeffry Beta Tenggara as speaker and panelist on the topic “Standards of Care in Early TNBC”
- Andhika Rahman as speaker on the topic “Unique Issues in TNBC”
- Ralph Girson Gunarsa as moderator with the topic “Tumor Board 2: Challenging Cases in TNBC” and as chairperson in the session “Genomics for Breast Cancer”
- Cosphiadi Irawan, Sp.PD-KHOM as a speaker with the topics and “HR Positive HER2 Negative and Bone Metastasis: Genomic Point of View” and “Do We Need or Not Need Adjuvant Chemotherapy in Hormonal Receptor Positive HER2 Negative EBC?”
Apart from that, there were also 6 specialist doctors from MRCCC and Siloam Hospital Denpasar Bali, namely Nadia Ayu Mulansari, Samuel Haryono, Alban Dien, Denny Handoyo, Rini Andriani, and Ni GA Arini Junita Putri Kardinal.
According to one of the expert doctors from MRCCC Siloam who was a panelist and speaker who raised the topic “Standards of Care in Early TNBC (Triple-negative breast cancer)” or standards of care for triple-negative breast cancer Jeffry Beta Tenggara, “Breast cancer is one of the the most common type of cancer worldwide and the leading cause of death among women.”
“In Indonesia itself, data from the Indonesian Ministry of Health states that 70% of breast cancer patients have entered stage 3 when detected. In fact, the prognosis for breast cancer patients’ chances of survival in an average of 5 years can reach 90-95% at Stage 1, 70-75 % Stage 2, and 10-25% Stages 3 and 4. Even though the prevalence is high, early detection and appropriate treatment can significantly reduce the risk of death from this disease. The high prevalence rate of breast cancer shows the importance of early detection, both independent and medical. ”
Furthermore, Jeffry said, “At APBCS 2024, we discussed and discussed with forum participants expert doctors from Asia Pacific, regarding standards of care for triple-negative breast cancer, starting from challenging cases of HER2-positive breast cancer. (for example changes in receptor status from preop disease to residual disease, Brain Mets, etc.), TNBC cases which are most frequently encountered in Indonesia, to challenging problems in cases of HR+ve breast cancer.” (RO/Z-1)
#Siloam #MRCCC #Semanggi #Hospital #Supports #Asia #Pacific #Breast #Cancer #Specialist #Meeting #Bali